Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock soared.
AI disclosure
Summary
The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.